Related Experiment Video
Updated: Aug 23, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Systemic treatment of hepatocellular carcinoma
Nathalie Ganne-Carrié1, Jean-Claude Trinchet
1Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, UPRES EA 3904, UFR SMBH, Université Paris, Bondy, France. nathalie.ganne@jvr.ap-hop-paris.fr
Abstract:
The results of systemic treatments for hepatocellular carcinoma are currently disappointing. In patients with advanced disease, none of the tested treatments (particularly systemic chemotherapy or hormonal treatment, such as tamoxifen) demonstrated an unequivocal benefit in terms of survival, and the trials including the largest numbers of patients have constantly been negative. After successful treatment of a first tumour, the most promising adjuvant strategy seems to be the use of interferon to treat patients who have hepatitis C infection. Nevertheless, only a few small randomized controlled trials have been performed and this result should be confirmed. Methodological improvement of clinical trials is needed, as major bias has often hampered the interpretation of the results. As recommended at a recent international conference in Barcelona, the most reliable methods for assessing the clinical outcome of a treatment in hepatocellular carcinoma are large randomized trials that each include a control arm of untreated patients, with overall survival as the primary endpoint, and an intention-to-treat analysis. New therapeutic strategies should be developed. Drugs such as vitamin D or vitamin A derivatives and inhibitors of COX-2 or angiogenesis could have a favourable influence on tumour growth. Some of these drugs are currently being tested in preliminary studies or even large randomized trials.
Insights
Systemic treatments for advanced liver cancer show disappointing survival benefits. Interferon may help after initial treatment for hepatitis C, but more research is needed to confirm its effectiveness.
Area of Science:
- Hepatocellular carcinoma (HCC) treatment outcomes
- Clinical trial methodology in oncology
Background:
- Systemic treatments, including chemotherapy and hormonal therapy, offer limited survival benefits for advanced hepatocellular carcinoma.
- Interferon shows promise as an adjuvant therapy for hepatitis C-infected patients post-tumor treatment, but requires further validation.
Purpose of the Study:
- To review the current efficacy of systemic treatments for hepatocellular carcinoma.
- To highlight the need for improved clinical trial methodologies in HCC research.
- To explore potential new therapeutic strategies for hepatocellular carcinoma.
Main Methods:
- Review of existing clinical trial data for systemic treatments in hepatocellular carcinoma.
- Discussion of methodological biases and recommendations for future trial design.
- Identification of emerging drug classes and therapeutic targets.
Main Results:
- Current systemic treatments for advanced hepatocellular carcinoma have not demonstrated significant survival advantages.
- Small-scale studies suggest interferon may be beneficial as an adjuvant therapy in specific patient populations.
- Methodological flaws in past trials have hindered definitive conclusions.
Conclusions:
- There is a critical need for improved, large-scale randomized controlled trials with robust methodologies for evaluating hepatocellular carcinoma treatments.
- New therapeutic avenues, including vitamin D/A derivatives and COX-2/angiogenesis inhibitors, warrant further investigation.
- Optimizing clinical trial design is essential for advancing hepatocellular carcinoma treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...